MENU
+Compare
CHGCY
Stock ticker: OTC
AS OF
Aug 28 closing price
Price
$21.97
Change
+$0.38 (+1.76%)
Capitalization
72.32B

CHGCY stock forecast, quote, news & analysis

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company... Show more

CHGCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for CHGCY with price predictions
Aug 28, 2025

Momentum Indicator for CHGCY turns positive, indicating new upward trend

CHGCY saw its Momentum Indicator move above the 0 level on August 21, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned positive. In of the 82 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CHGCY's RSI Oscillator exited the oversold zone, of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 56 cases where CHGCY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CHGCY just turned positive on August 26, 2025. Looking at past instances where CHGCY's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CHGCY advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .

CHGCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

CHGCY moved below its 50-day moving average on August 07, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHGCY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.371) is normal, around the industry mean (9.441). P/E Ratio (26.966) is within average values for comparable stocks, (23.751). CHGCY's Projected Growth (PEG Ratio) (4.361) is slightly higher than the industry average of (1.853). CHGCY has a moderately low Dividend Yield (0.009) as compared to the industry average of (0.027). CHGCY's P/S Ratio (8.913) is very high in comparison to the industry average of (3.410).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CHGCY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHGCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Dividends

CHGCY paid dividends on April 12, 2024

Chugai Pharmaceutical Co., Ltd. CHGCY Stock Dividends
А dividend of $0.13 per share was paid with a record date of April 12, 2024, and an ex-dividend date of December 28, 2023. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Pfizer (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 88.99B. The market cap for tickers in the group ranges from 72.83K to 656.17B. LLY holds the highest valuation in this group at 656.17B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -1%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 12%. SCLX experienced the highest price growth at 6%, while MDCX experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -1%. For the same stocks of the Industry, the average monthly volume growth was -52% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 32
P/E Growth Rating: 100
Price Growth Rating: 54
SMR Rating: 100
Profit Risk Rating: 79
Seasonality Score: -10 (-100 ... +100)
View a ticker or compare two or three
CHGCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
1-1 Nihonbashi-Muromachi 2-Chome
Phone
+81 332816611
Employees
7432
Web
http://www.chugai-pharm.co.jp